Category: Uncategorized

Symphogen, a private biopharmaceutical Company developing recombinant antibody mixtures, announced today that Kirsten Drejer, Chief Executive Officer, will present an update on the Company at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2016 from 11:00 AM - 11.25 AM at San Francisco's Westin St. Francis Hotel in the Elizabethan D meeting room. The company announced earlier this month a strategic collaboration with Baxalta Incorporated, worth up to $1.6 billion plus royalties, to develop immuno-oncology candidate products.

Partnership aims to advance development of novel immune checkpoint therapies as Baxalta expands oncology leadership in orphan diseases. Symphogen to receive $175 million (€160 million) upfront, in addition to potential future milestone payments and royalties.
Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, and Symphogen, a private biopharmaceutical company developing recombinant antibodies and antibody mixtures, today announced a broad strategic immuno-oncology collaboration.

Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that Genentech, a member of the Roche Group, has dosed for the first time in humans a clinical trial candidate containing a Symplex generated antibody conjugated to an undisclosed active agent.

Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today the closing of a EUR 67.5 million convertible debt facility, secured from existing investors, led by Novo A/S and the Danish pension fund PKA. The proceeds will be used to progress the company's pipeline, specifically Sym004, a novel antibody mixture and its lead clinical program currently in a multi-center Phase 2b study in metastatic colorectal cancer patients with disease resistance or refractory to anti-EGFR antibody therapies. In addition, funds are earmarked to advance to the clinic both of the company's other fully owned assets, the pan-HER product candidate, Sym013, a mixture of six antibodies targeting each of EGFR, HER2 and HER3 and its MET product candidate, Sym015, a mixture of two antibodies targeting the MET receptor for treatment of patients with MET-amplified tumors. Symphogen is also deploying its proprietary mAb mix approach to its immuno-oncology research programs.

The closing of the convertible loan facility brings Symphogen's total pro-forma cash resources to a total of EUR 110 million.

Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today several new corporate initiatives that reposition the company to focus on its proprietary pipeline of clinical oncology programs. The announcements address the regained rights to Sym004, a novel antibody mixture currently in a Phase 2b program, and a prioritization of the company's discovery activities in immuno-oncology.

Selexis SA, a serial innovation company with proven technologies for biologic drug discovery and mammalian cell line development announced today that Selexis and Symphogen A/S have entered into a commercial license agreement and signed the continuation of their R&D license agreement. Symphogen has licensed the rights to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the development of recombinant monoclonal antibody (MAb) mixtures for the treatment of various cancers and infectious diseases.
Symphogen has developed unique technologies for the controlled, reproducible production of highly characterized mAb mixtures manufactured in a single batch.

Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that its collaborative partner, Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, Merck Serono has initiated two new clinical studies evaluating Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR). The trials are a Phase 2b study in patients with metastatic colorectal cancer (mCRC) and a Phase 1b study in patients with Non-Small Cell Lung Cancer (NSCLC). Symphogen also reports that it is eligible to receive two milestone payments from Merck for achieving certain agreed goals in the collaboration, related to the bi-weekly dosing study and the mCRC study.

Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today reported preliminary safety and exploratory efficacy data from a Phase 1 clinical study of Sym004, an investigational anti-EGFR monoclonal antibody mixture, administered biweekly, that will be presented in a poster at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting being held May 30 – June 3, 2014 in Chicago, IL. The poster, entitled, Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (29 pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment (abstract #3551) will be on view in the poster session on Gastrointestinal (Colorectal) Cancer (31 May 2014, 8:00 – 11:45 AM, McCormick Place Convention Center in Chicago, IL). Sym004 is a drug mixture of two mAbs targeting non-overlapping epitopes of EGFR which have been shown in pre-clinical studies to demonstrate synergistic inhibition of EGFR.